The Global Procurement Fund (GPRO) is a non-profit organization, started by the CDA Foundation, with the goal of expanding access to needed medicines and diagnostics through pooled purchasing.
GPRO provides competitive prices through economies of scale, assured quality, and access to more products. GPRO pools orders from member countries and uses international competitive bidding to purchase products at negotiated prices. The pooled procurement will result in lower prices than most countries can negotiate on their own. GPRO only considers quality products and manufacturers for its procurement.
For more information, visit www.gprofund.org.
The John Martin Foundation (DBA The John C. Martin Foundation) is a non-profit privately-funded organization established in 2016 in the U.S. with the aim to support establishment of sustainable healthcare for patients in socially and economically deprived settings by facilitating access to knowledge and care to prevent and treat endemic diseases.
The Foundation mainly focuses on HIV/AIDS, viral hepatitis and associated disease areas supporting knowledge-building among healthcare providers, disease surveillance to better define public health burdens, prevention of transmission, and healthcare infrastructure establishment for impoverished populations.
Unitaid is an international organization that invests in new ways to prevent, diagnose and treat HIV/AIDS, hepatitis C, tuberculosis and malaria more quickly, more affordably and more effectively. It accelerates access to innovation so that critical health products can reach the people who most need them. Unitaid’s work facilitates large-scale introduction of health products through funding by the Global Fund, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and by governments.
Unitaid is helping to defeat the hepatitis C epidemic in the context of HIV co-infection by investing US$ 58 million in three grant projects (2015-2019). The projects seek to develop new and simpler diagnostics, establish innovative models for screening and treatment in HIV/HCV co-infected populations, and devise cost-reduction strategies.
For more information: https://unitaid.org
Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate.
For more information, visit www.wellcome.ac.uk.
In partnership with EndHEP2030.
ZeShan Foundation ("ZeShan") is a Hong Kong-based family foundation with an international reach. By practicing strategic giving, ZeShan addresses overlooked or long-neglected needs in communities and society and tackles their root causes through a systems approach.
ZeShan’s philanthropic endeavors are underpinned by three guiding principles: engaged philanthropy, strategic partnership, and lasting impact. To maximize the impact of its initiatives, ZeShan creates synergies and leverages opportunities with like-minded funders and organizations that are dedicated to the causes that ZeShan supports.
In 2006, ZeShan made it a strategic focus for its Health program: the elimination of viral hepatitis, hepatitis B virus in particular, as a public health threat. Since then, ZeShan has formed multi-lateral partnerships in China, the Western Pacific Region and around the world. A unique tripartite partnership between ZeShan, US CDC and WHO led to a successful roundtable summit on funding for elimination of viral hepatitis (June 20 - 21, 2016. Hong Kong China). The conclusions of the Summit led to the establishment of the Fund for Elimination of Viral Hpatitis (d.b.a. "EndHEP2030"), which is to be launched at the World Hepatitis Summit (November 2017. Sao Paulo, Brazil.)
ZeShan has identified five areas for support: Health; Education; Human Services and Social Development in Hong Kong; Advancement of Philanthropy; Disaster Relief and Community Rebuilding. For more information on the Foundation and its programs, please visit our web site at www.zeshanfoundation.org.
EASL started as a small group of 70 hepatologists from 15 European countries who came together to share best medical practice in April 1966.
Over half a century later EASL has evolved into a major European Association with international influence dedicated to the liver and liver disease.
EASL has over 4,300 members from all over the world and provides an annual platform, The International Liver Congress™, for 10,000 liver experts to meet and discuss latest scientific research.
EASL has given rise to many international clinical trials and research collaborations to the benefit of patients all over the world.
For more information, visit www.easl.eu.